-18%

est. 2Y upside i

HealthcarePre-Seed

Apothékary started with our founder, Shizu Okusa, and her family’s traditional Japanese approach to healing — using nature as medicine instead of over-the-counter fixes. In many Eastern cultures, traditional medicine in the form of plants and herb has been used for centuries to address the root cause of common ailments.

Rank

#435

Sector

Wellness

Est. Liquidity

~4Y

Data Quality

Data: High

Apothékary presents a moderate upside opportunity driven by its strong growth (projected $30M-$50M revenue in 2026) and profitability.

Last updated: March 10, 2026

Bull (37%)+300%

Apothékary successfully leverages its strategic partnership with Shiseido and expands its unique liquid herbal supplement line, achieving market leadership in a rapidly growing niche. Revenue surpasses $110M by 2028, justifying a $1.16B+ valuation at a premium multiple, driven by strong brand loyalty and continued retail penetration.

Base (38%)+75%

Apothékary maintains its strong growth trajectory and profitability, solidifying its position in the plant-based wellness market through expanded retail presence and a loyal direct-to-consumer base. Revenue reaches approximately $65-70M by 2028, leading to an acquisition or IPO at around $500M-$550M valuation.

Bear (25%)-75%

Intensified competition from larger incumbents and new entrants, coupled with persistent negative customer feedback on product efficacy or service, slows growth significantly. Revenue stalls around $35-40M by 2028, leading to a down round or a low-multiple acquisition at $70-80M, where the $21M preference stack severely impacts common stock value.

Est. time to liquidity~3.5 years

Preference Stack Risk

moderate

Funding Intensity

7%

Investors hold $21M in liquidation preferences, representing 7.24% of the current $290M valuation, which would impact common stock returns in an exit at or below this valuation.

Dilution Risk

moderate

As a Pre-Series A company, Apothékary will likely undergo several more funding rounds to fuel its ambitious retail expansion and product development, leading to further dilution for existing equity holders.

Secondary Liquidity

limited

A secondary market valuation exists, implying some liquidity for early investors or founders, but it is not explicitly stated as active or accessible for all employees.

Questions to Ask at the Interview

Strategic questions based on Apothékary's data — designed to show you've done your homework.

  • 1

    “Given the rapid expansion into major retailers like Whole Foods and Ulta, how is Apothékary ensuring consistent product education and customer experience across diverse sales channels, especially considering past feedback on product usage and customer service?”

  • 2

    “With projected revenue reaching $30M-$50M in 2026 and a stated goal of leading the liquid herbal movement, what are the key strategic initiatives to maintain this growth trajectory and defend market share against larger incumbents and emerging competitors in the crowded wellness space?”

  • 3

    “Apothékary has stated profitability and potentially not needing to raise further capital. How does the company balance this capital efficiency with the ambitious growth plans, and what is the anticipated timeline and strategy for a liquidity event for employees holding equity?”

Community

Valuation Sentiment

Our model estimates -18% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.